ILMN — Illumina, Inc.
Is ILMN overbought or oversold? Here is the current MarketMoodz read.
Illumina, Inc. (ILMN) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $198.00. The rating moved from Neutral to Oversold on November 3, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$198.00
- Last changeMoved from Neutral to Oversold on November 3, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
See all oversold Healthcare stocks →
AI analysis
Illumina benefits from durable competitive advantages in sequencing hardware and high-margin consumables, supported by secular growth in genomics and increasing clinical applications. Near-term performance will depend on instrument order cadence and clinical adoption rates, while medium-term upside is driven by expansion into diagnostics and recurring revenue growth. Key uncertainties include regulatory/litigation outcomes, competitive pricing pressure, and cyclical capital spending that could create volatility.
Key factors
- Market leadership in next-generation sequencing platforms with a large installed base that drives recurring consumables revenue.
- High-margin consumables and services business that provides revenue visibility and resilience versus one-time instrument sales.
- Growing clinical adoption (oncology, NIPT, liquid biopsy and other diagnostic applications) supports transition from research to higher-volume clinical markets.
- Long-term secular tailwinds from genomics-driven research, personalized medicine and increased sequencing penetration across use cases.
- Solid cash generation potential enabling R&D investment, product refresh cycles and potential opportunistic M&A or share repurchases.
- Relative insulation from short-term macro shocks because of recurring consumables demand, though capital-equipment purchases remain cyclical.
Risks
- Regulatory, antitrust and litigation risk tied to prior strategic actions and industry consolidation; outcomes could include fines, restrictions or ongoing legal costs.
- Intensifying competition from large life-science companies and lower-cost sequencing providers that could pressure pricing and share.
- Cyclicality in capital-equipment spending at research institutions and clinical labs could cause near-term volatility in instrument orders.
- Reimbursement and payer dynamics for clinical tests (NIPT, oncology assays) that could slow clinical uptake or reduce test prices.
- Supply-chain or manufacturing disruptions that could affect instrument deliveries and consumables supply.
- Execution risk on new product launches or commercialization outside core research markets.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ILMN — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.